ArticleCommunications medicine2025
Clinically feasible liver tumour cell size measurement through histology-informed in vivo diffusion MRI.
Article in Communications medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
Abstract
backgroundInnovative diffusion Magnetic Resonance Imaging (MRI) models enable the non-invasive measurement of cancer biological properties in vivo. However, while cancers frequently spread to the liver, models tailored for liver application and easy to deploy in the clinic are still sought. We fill this gap by delivering a practical, clinically-viable framework for liver tumour diffusion imaging, informing its design through histology.
methodsWe compare MRI and histological data from mice and cancer patients, namely: MRI and hemaotxylin-eosin (HE) stains from N = 7 fixed mouse livers; MRI of N = 38 patients suffering from liver solid tumours, N = 18 of whom with HE biopsies. We study five diffusion models, ranking them according to a total MRI-histology correlation score. Afterwards, we test metrics from the top-ranking model on our cohort, assessing their sensitivity to cell proliferation (Ki-67 staining, N = 10), evaluating their association with tumour volume (N = 140 tumours), and comparing them across primary cancer types.
resultsWe select a dMRI signal model of restricted intra-cellular diffusion with negligible extra-cellular contributions, which maximises radiological-histological correlations (total score: 0.625). The model provides cell size and density estimates that i) correlate with histology (e.g., for cell size: r = 0.44, p = 0.029), ii) are associated to Ki-67 cell proliferation (for MRI cell density: r = 0.80, p = 0.006) and tumour volume (r = 0.40, p < 10
conclusionsOur biologically meaningful approach may complement standard-of-care radiology, and become a new tool for enhanced cancer characterisation in precision oncology.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.